Clinical Trials Browser

Phase 2 × Everolimus × Endocrine × Clear all

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2 Recruiting

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2 Recruiting

Advanced Lung Neuroendocrine Tumor

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT03950609 2026-01-09

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT00113360 2025-05-01

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2 Completed

67 enrolled 6 charts

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2 Completed

21 enrolled 8 charts

Neuroendocrine Tumors

NCT01678664 2024-09-25

EVACEL

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT02031536 2023-06-29

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Phase 2 Terminated

2 enrolled 8 charts

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02687958 2023-05-30

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Phase 2 Unknown

Carcinoma, Neuroendocrine

NCT01263951 2021-10-26

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

Phase 2 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02695459 2021-04-20

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Phase 2 Unknown

Carcinoma, Neuroendocrine

NCT01563354 2021-04-02

LUNA

Phase 2 Completed

124 enrolled 18 charts

Carcinoma, Neuroendocrine

NCT02113800 2020-10-28

EVINEC

Phase 2 Completed

EndocrineLymphoidNET

Lymphoma, Follicular, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2 Terminated

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02248012 2019-12-19

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Phase 2 Completed

Carcinoma, Neuroendocrine

NCT00688623 2019-01-25

RAMSETE/CDE16

Phase 2 Completed

73 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT02305810 2018-11-07

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

Phase 2 Completed

EndocrineGastrointestinal

Pancreatic Neuroendocrine Tumour Metastatic

NCT01374451 2016-12-20

COOPERATE-2

Phase 2 Terminated

160 enrolled 17 charts

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Terminated

62 enrolled 7 charts

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01152827 2015-05-20

PheoCarcRAD001

Phase 2 Completed

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01164176 2014-12-02

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Phase 2 Completed

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT01118065 2013-08-12

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Phase 2 Unknown

EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT00607113 2013-07-18

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

Phase 2 Completed

41 enrolled 6 charts

Carcinoma, Neuroendocrine

NCT00363051 2013-05-10

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Phase 2 Completed

160 enrolled 17 charts

EndocrineGastrointestinalNET

Carcinoma, Neoplasms, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors